A meta-analysis of 6 trials with 4,036 participants found tirzepatide produced dose-dependent weight loss of 7.7 to 11.8 kg compared to placebo, with gastrointestinal side effects being the main trade-off.
-11.8 kg at 15 mgMean weight loss compared to placebo across 6 randomized trials — representing a 12.4% reduction in body weight
What the researchers found
Across 6 RCTs with 4,036 participants (12-72 weeks):
**Weight loss vs placebo:**
- Tirzepatide 5 mg: -7.7 kg (-8.1%)
- Tirzepatide 10 mg: -11.6 kg (-11.9%)
- Tirzepatide 15 mg: -11.8 kg (-12.4%)
- All doses: p<0.001
Tirzepatide also significantly reduced BMI and waist circumference.
**Side effects at 15 mg vs placebo:**
- Nausea: OR 4.2 (4.2× more likely)
- Vomiting: OR 7.0 (7× more likely)
- Diarrhea: OR 2.8 (2.8× more likely)
All three doses showed a clear dose-response relationship for both efficacy and side effects.
Why it matters
This meta-analysis quantifies what individual trials suggested: tirzepatide produces weight loss that rivals bariatric surgery for some patients. The 12.4% body weight reduction at the highest dose exceeds what earlier GLP-1-only drugs achieved, validating the dual-receptor approach. These numbers helped establish tirzepatide as a leading option for medically managed weight loss.
How the study worked
Systematic review and meta-analysis searching PubMed, Embase, and Cochrane for randomized controlled trials comparing tirzepatide to placebo. Six studies with 4,036 participants were included, ranging from 12 to 72 weeks. Mean differences were calculated for continuous outcomes and odds ratios for binary outcomes. Risk of bias was assessed using the Cochrane RoB-2 tool. Registered in PROSPERO (CRD42022348576).
What this study cannot tell us
Only 6 trials were available for analysis, limiting the statistical robustness for subgroup analyses. Trial durations varied from 12 to 72 weeks, and the pooled analysis may not fully account for duration-dependent effects. Long-term weight loss maintenance and safety beyond 72 weeks were not assessed. The gastrointestinal side effect rates may discourage some patients from continuing treatment. Most trials included diabetes patients, so results may not perfectly extrapolate to all obese populations.
How to read the evidence
This is a well-conducted meta-analysis of 6 randomized controlled trials with PROSPERO registration and Cochrane risk-of-bias assessment. The evidence quality is high, limited mainly by the relatively small number of available trials at the time of analysis. The consistent dose-response across studies strengthens confidence in the findings.
When this study was published
Published in 2023 with data through July 2022, this meta-analysis captured the early clinical trial evidence for tirzepatide. Since then, additional trials (including the SURMOUNT obesity program) have provided further data, generally confirming and extending these findings.
The bigger picture
This meta-analysis was published as tirzepatide was transitioning from diabetes treatment to obesity indication. The consistent, large weight loss effects across multiple trials helped build the case for its approval as a weight management drug (Zepbound). The data also established tirzepatide as the benchmark against which newer triple agonists and next-generation peptide drugs are being compared.
Questions still open
- Does the weight loss achieved with tirzepatide persist long-term, or does weight regain occur after discontinuation as seen with other weight loss drugs?
- Can the gastrointestinal side effects be mitigated through slower dose titration or combination strategies without sacrificing efficacy?
- How does tirzepatide's weight loss compare head-to-head with high-dose semaglutide (2.4 mg) in obesity patients?
Common questions
How much weight can I expect to lose on tirzepatide?
Are the side effects worth it?
Read the original research
Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials.
International journal of obesity (2005), 47(10), 883-892
Citation
de Mesquita, Yasmin Luz Lima; Pera Calvi, Izabela; Reis Marques, Isabela; Almeida Cruz, Sara; Padrao, Eduardo Messias Hirano; Carvalho, Pedro Emanuel de Paula; da Silva, Caroliny Hellen Azevedo; Cardoso, Rhanderson; Moura, Filipe Azevedo; Rafalskiy, Vladimir Vitalievich. (2023). Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials.. International journal of obesity (2005), 47(10), 883-892. https://doi.org/10.1038/s41366-023-01337-x